**Core Concept**
The treatment of Parkinson's disease often involves medications that target the dopaminergic and cholinergic systems. In this context, decreasing brain cholinergic activity can help alleviate symptoms by increasing the balance between dopamine and acetylcholine.

**Why the Correct Answer is Right**
The correct answer is levodopa, which acts by increasing dopamine levels in the brain. However, levodopa does not directly decrease brain cholinergic activity. The correct answer is actually **Benzatropine (Benzhexol)**, which is an anticholinergic agent that decreases brain cholinergic activity by blocking the action of acetylcholine at muscarinic receptors. This leads to an increase in the activity of dopaminergic neurons, thereby alleviating Parkinsonian symptoms.

**Why Each Wrong Option is Incorrect**
- **Option A:** Levodopa acts by increasing dopamine levels in the brain and does not directly decrease brain cholinergic activity.
- **Option C:** Dopamine agonists like Pramipexole and Ropinirole mimic the action of dopamine and do not decrease brain cholinergic activity.

**Clinical Pearl / High-Yield Fact**
Anticholinergic medications like Benzatropine can cause side effects such as dry mouth, constipation, and urinary retention due to their effect on the muscarinic receptors in the parasympathetic nervous system.

**Correct Answer:** B. Benzatropine (Benzhexol)